title: Effects of peptide YY on the human cardiovascular system: reversal of responses to vasoactive intestinal peptide.
abstract: Peptide YY (PYY) reverses the increased intestinal secretion stimulated by vasoactive intestinal peptide (VIP) in humans. VIP also dilates blood vessels, so we investigated the effect of PYY on the cardiovascular system. Six volunteers received PYY, 0.4 and 1.2 pmol.kg-1 x min-1 i.v. for 2 h, reproducing plasma levels seen postprandially and during a diarrheal illness, respectively. Cardiac function was assessed by echocardiography. PYY infused at 0.4 pmol.kg-1 x min-1 had no effect on cardiovascular parameters. PYY infused at 1.2 pmol.kg-1 x min-1 caused a fall in both stroke volume from 128 +/- 8 to 110 +/- 8 ml/beat (mean +/- 95 confidence interval, P < 0.01) and cardiac output from 7.2 +/- 0.4 to 6.1 +/- 0.4 l/min (P < 0.01). Effects of infusion of PYY into the brachial artery at doses of 0-16 pmol/min were assessed using venous occlusion plethysmography in six subjects. PYY infusion caused a dose-dependent fall in forearm blood flow. Six subjects received VIP, 5 pmol.kg-1 x min-1 i.v., causing a rise in heart rate from 55 +/- 3 to 70 +/- 3 beats/min and increased cardiac output from 7.3 +/- 1.1 to 13.1 +/- 1.1 l/min. The addition of PYY, 0.4 pmol.kg-1 x min-1 i.v., did not affect the heart rate significantly but decreased the cardiac output to 10.4 +/- 1.1 l/min (P < 0.01). Infusions of PYY into the brachial artery at 5 pmol/min decreased local vasodilation induced by VIP infused at 2 pmol/min at the same site by 40% (P < 0.01), even though this dose of PYY had no significant effect on local blood flow when given alone.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Royal Postgraduate Medical School, London, United Kingdom.
authors.forename: R J
authors.initials: RJ
authors.lastname: Playford
authors.forename: M A
authors.initials: MA
authors.lastname: Benito-Orfila
authors.forename: P
authors.initials: P
authors.lastname: Nihoyannopoulos
authors.forename: K A
authors.initials: KA
authors.lastname: Nandha
authors.forename: J
authors.initials: J
authors.lastname: Cockcroft
authors.forename: S
authors.initials: S
authors.lastname: Todd
authors.forename: M A
authors.initials: MA
authors.lastname: Ghatei
authors.forename: J
authors.initials: J
authors.lastname: Domin
authors.forename: S R
authors.initials: SR
authors.lastname: Bloom
authors.forename: J
authors.initials: J
authors.lastname: Calam
mesh_terms: D000328:Adult; D002319:Cardiovascular System / Q000000981:diagnostic imaging / Q000187:drug effects*; D015150:Echocardiography, Doppler; D005260:Female; D005542:Forearm / Q000098:blood supply; D005768:Gastrointestinal Hormones / Q000494:pharmacology; D006801:Humans; D007262:Infusions, Intravenous; D007269:Injections, Intra-Arterial; D008297:Male; D009994:Osmolar Concentration; D019894:Peptide YY; D010455:Peptides / Q000494:pharmacology*; D015203:Reproducibility of Results; D014660:Vasoactive Intestinal Peptide / Q000037:antagonists & inhibitors / Q000097:blood / Q000494:pharmacology*
chemical_list: D005768:Gastrointestinal Hormones; D010455:Peptides; D019894:Peptide YY; D014660:Vasoactive Intestinal Peptide